All In Biotech

Drug Trial Radar · NCT04958122

Cefixime Clinical Trial

Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis

Last checked: Nov 20, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jun 20, 2021

Primary completion

Jan 1, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
University of Southern CaliforniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AIDS Healthcare Foundation; Universidad Peruana Cayetano Heredia
First posted
Jul 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.

Conditions

  • Syphilis
  • Human Immunodeficiency Virus

Interventions

  • Cefixime 400mgDrug

    Oral cefixime 400 mg, one capsule, twice a day for 10 days

  • benzathine penicillinDrug

    Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response to treatmentTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.